Immunotherapy of breast cancer - Wikidata - wikimedia - TriplyDB

Immunotherapy of breast cancer

Immunotherapy of breast cancer

http://www.wikidata.org/entity/Q57134389

about

Peptide-Based Treatment: A Promising Cancer Therapy The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.T cell coinhibition and immunotherapy in human breast cancer Development of automated quantification methodologies of immunohistochemical markers to determine patterns of immune response in breast cancer: a retrospective cohort study.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?A review of therapeutic aptamer conjugates with emphasis on new approaches.Dendritic cell-based vaccines: clinical applications in breast cancer.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Breast cancer stem cells and the immune system: promotion, evasion and therapy.Safety and efficacy study of lung cancer stem cell vaccine.Awareness and current knowledge of breast cancer.Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?Tucaresol down-modulation of MUC1-stimulated human mononuclear cells.Harnessing the immune system in the battle against breast cancer.

P2860

Q26777032-93D804C8-22C9-4ECB-806B-31115B642294 Q33636990-7A88D90C-9B32-4EDF-9C89-1BFCC02F7E51 Q33936154-8EB1F349-83A3-483A-8B07-1DD4FCDDEA83 Q34024612-FF03B338-B1C0-4D68-8767-0DA33BB0FBA8 Q34988382-D0F8930D-39D3-4AE6-BF20-11B3276A4CA6 Q36605526-8F9B1B94-D94A-4215-8AF9-172BF4A393D7 Q37277378-8F7C0379-8681-4D45-A6D4-9C46C2F1B65C Q38206821-D6CF54ED-E48A-478C-A423-73778D291FCC Q38215394-B6049287-52FF-472E-9B3C-9B5D4A570C8A Q38226597-1C86FA00-1F4F-4B63-84DE-4533895A4D57 Q40166620-FA32650F-A765-486A-8578-DC23D930B50E Q42176053-C557500B-EB71-432E-80D0-2486E73E20CD Q42326285-155CB8E4-A278-47ED-A972-F5069742085D Q44995384-5A76FF2C-E23F-46AA-BA68-9199CCE764F3 Q49884762-F7709739-1D36-4E58-9557-498053340E88

P2860

Immunotherapy of breast cancer

http://www.wikidata.org/entity/Q57134389

description

im April 2012 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2012

@uk

name

Immunotherapy of breast cancer

@en

Immunotherapy of breast cancer

@nl

type

label

Immunotherapy of breast cancer

@en

Immunotherapy of breast cancer

@nl

prefLabel

Immunotherapy of breast cancer

@en

Immunotherapy of breast cancer

@nl

P1433

Q57134389-95CC4C02-DD47-4006-987E-D0C2860D02CB

P1476

Q57134389-5E9343A7-8FA2-42EF-B984-B3B1998C699A

P2093

Q57134389-7098061A-990C-4B76-BAD5-08A4CD14CD00

P2860

Q57134389-025320BD-99DF-4D0F-BBB3-4F947DBB78D3

Q57134389-081436CE-6B23-4867-A624-90E57962EDFE

Q57134389-08A5B35C-EEEF-4CC4-9B77-1F78F064882F

Q57134389-09C9124E-3054-492F-B9A1-4D453768F021

Q57134389-1BCA18EB-DFAD-4A06-8AE2-5CA7ED771CFD

Q57134389-1F66FE6F-8340-468E-B785-CC0DE3B3F562

Q57134389-269E2B62-BF02-4DCB-B410-63C455BA4233

Q57134389-29C51031-24DA-46CF-916D-5F9B03E43FC9

Q57134389-2AD7A9E6-D03A-4525-8DD5-84CCC4430DA9

Q57134389-2BE5BC06-EDB3-400A-8C5F-0E5A1178EA11

P304

Q57134389-62C7DCB6-9405-45A9-A137-FCF3194A3368

P31

Q57134389-1C653C56-323F-4057-B982-A74CFECA4754

P356

Q57134389-EE8B0C15-3E0E-48A4-A193-7F2EC245B766

P407

Q57134389-B2F246C3-4627-40A5-AEC0-F7ADA5654591

P433

Q57134389-1C822783-AA4C-43C2-B999-F1E667798810

P478

Q57134389-5654E9AF-894A-42F9-969D-CC7E6BB0556D

P577

Q57134389-C9E3094C-DD54-4EE2-8954-A5F235A42486

P698

Q57134389-145EFEA6-9336-4086-9D86-FAA5992484A6

P921

Q57134389-408EF6E7-F389-4682-ACED-921084ADEAB1

P356

14712598.2012.665445

P1433

Expert Opinion on Biological Therapy

P1476

Immunotherapy of breast cancer

@en

P2093

Stephen E Wright

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Breast cancer vaccines: a clinical reality or fairy tale?

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

P304

479-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.665445

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22413825

http://www.w3.org/2001/XMLSchema#string

P921